Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD
March 31, 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD
March 15, 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference
March 10, 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD
February 24, 2021 05:30 ET
|
Opthea Limited
Following consultations with US FDA and EU EMA, two pivotal Phase 3 clinical trial designs are finalized to assess 2 mg OPT-302 administered 4-weekly or 8-weekly in combination with Lucentis® (ShORe...
Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 17, 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Announces Pricing of Initial Public Offering in the United States
October 16, 2020 11:20 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Announces Launch of Proposed Initial Public Offering in the United States
October 11, 2020 20:00 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 11, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea to Appoint Dr Jeremy Levin as Chairman of the Board
October 05, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Files Registration Statement for Proposed Initial Public Offering in the United States
September 25, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Appoints US-Based Non-Executive Director
September 10, 2020 12:04 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- The directors of Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent...